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Abstract  
Introduction: Diabetic nephropathy remains the most common cause of renal disease in 
patients diagnosed with type 2 diabetes. 
Aims: We conducted a systematic review and meta-analysis of published observational 
evidence to assess the difference in the prevalence and progression of diabetic 
nephropathy, and the development of end-stage renal failure in three ethnicities with type 2 
diabetes. 
Methods: Relevant studies were identified in a literature search of MEDLINE, EMBASE, and 
reference lists of relevant studies to May 2018. We decided a priori that there were no 
differences in the prevalence and progression of diabetic nephropathy, and the development 
of end-stage renal failure in the three ethnicities with type 2 diabetes. Pooled relative risks of 
microalbuminuria by ethnicity were estimated by fitting three random effects meta-analyses 
models.  A narrative synthesis of the nephropathy progression in the studies was done. The 
review was registered on PROSPERO (registration number CRD42018107350).  
Results:  
Thirty-two studies with data on 153,827 unique participants were eligible. The pooled 
prevalence ratio of microalbuminuria in South Asian compared to White Europeans was 1.14 
(95% CI: 0.99, 1.32 p=0.065). For African Caribbeans vs South Asians the pooled 
prevalence ration was 1.08 (95% CI: 0.93, 1.24), p=0.327. Results surrounding renal decline 
were inconsistent with preponderance towards a high rate of disease progression in South 
Asians compared to White Caucasians. The estimated pooled incident rate ratio for end 
stage renal disease was significantly higher in African Caribbeans vs White Europeans 2.75 
(95% CI: 2.01, 3.48 p<0.001) 
Conclusion: This review did not find a significant link between ethnicity (South Asians, 
White Europeans and Afro-Caribbeans) and the prevalence of microalbuminuria. However, 
the incident rate ratio of end stage renal disease in African Caribbeans compared to White 
Europeans was significantly higher. Further research is needed to explore the potential non-
albuminuric pathways of progression to end stage renal failure. 
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Introduction 
Diabetes is a substantial public health problem and the most common cause of end stage 
renal disease globally. The relative contribution of type 2 diabetes (T2DM) to the increasing 
burden of end stage kidney disease has been well established (1) (2). With the rising 
epidemic of T2DM, obesity and an ageing population, it is anticipated that the burden of 
renal disease on health systems will increase further.  
A migrant is defined as someone who has either changed their usual country of residence or 
settled in another country such as the US, Europe or Australia or is a descendant of the 
former (3). Globally migration is increasing, with the number of international migrants 
reaching 258 million in 2017 (4). 79.6 million originated from Asia. Many of these migrants 
were of South Asian origin with 17 million originating from India alone. 24.7 million of the 
migrants were of African origin, making Africa the fourth largest contributor in 2017 (4).  
The 2011 UK Census demonstrated an increase in the ethnic minority population. South 
Asian and Afro-Caribbean migrants comprise about 8% and 3% of the total population in the 
UK, respectively. Together these ethnicities make up more than half of the UK's non-
European population (5).  
It is well established that South Asian and Afro-Caribbean adults develop T2DM at a much 
younger age compared to their White counterparts and exhibit a marked predisposition to 
cardiovascular disease and end-stage renal failure (6) (7). In the UK, a higher incidence of 
central obesity and vascular disease has been reported in migrant South Asians when 
compared to White Europeans despite lower levels of cardiovascular risk factors (7) (8). It is 
likely that higher levels of insulin resistance drive the higher rates of vascular disease and 
diabetes in this population (9).  
A number of studies indicate that the risk for the development and progression of diabetic 
nephropathy varies among different populations (8) (10) (11). The incidence of end stage 
kidney disease due to both T1DM and T2DM is higher among South Asians compared to 
White Europeans (12), (13). However, the literature on diabetic nephropathy in ethnic groups 
is sparse and varied and it is not clear whether progression or higher levels of urine 
albumin excretion influence similar rates of e-GFR decline among different ethnic 
populations despite similar competing risks and therefore may impact rates of prevalence of 
end stage renal failure. 
The objective of this systematic review and meta-analysis was to examine and analyze 
published evidence on the prevalence of albuminuria, rates of disease progression and end 
stage renal disease outcomes in White European compared to South Asian and Afro-
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Caribbean adults with nephropathy due to T2DM. We decided a priori that there were no 
differences in the prevalence and progression of diabetic nephropathy, and the development 
of end-stage renal failure in various ethnicities with type 2 diabetes. 
 
Methods 
Search strategy 
Medline (1950 to week 1 May 2018), Embase (1980 to week 1 May 2018), the Cochrane 
Central Register of Controlled Trials (CENTRAL) and the Cochrane Renal Group trial 
register were searched using a broad search strategy to identify all potentially relevant 
publications for this review. Population search terms, including Medical Subject Heading 
0H6+µ$VLDQ&RQWLQHQWDOUHJLVWU\JURXS¶µ$VLDQV¶,QGLDQV¶µ3DNLVWDQLV¶µ%DQJODGHVKLV¶
µ$IUR-&DULEEHDQV¶DQGµHWKQLFPLQRULW\SRSXODWLRQ¶ZHUHFRPELQHGZLWK0H6+WHUPVWKDW
covered T2DM, diabetes mellitus, nephropathy, renal disease, end-stage renal disease 
(ESRD) and albuminuria. Free text terms were also used to optimise search sensitivity. 
Reference lists were checked to identify any further articles. Studies were not limited to the 
English language, however none of the relevant studies required translation to the English 
language. 
Study selection 
Only studies comparing the ethnicities; White Europeans, South Asians and Afro-
Caribbeans, in whichever combination, in adult T2DM patients with diabetic nephropathy 
were included. Where studies compared ethnicities other than the ones included in our 
selection criteria, data for South Asians, White Europeans and African Caribbeans was 
H[WUDFWHGVHSDUDWHO\:HH[FOXGHG³$PHULFDQ$VLDQV´RU³$VLDQV´XQOHVVFOHDUO\GHILQHG
since they may comprise of Arab/ Chinese/ Hmong/ Lebanese/ Turkish/ Bangladeshi/ 
Filipino/ Indian/ Korean/ Pakistani/ Taiwanese populations and therefore could not be 
categorized as South Asians or people originating from the Indian subcontinent. We used 
WKHWHUP³$IULFDQ&DULEEHDQV´WRPHDQSHRSOHRIAfrican descent wherever they are living in 
world. 
 Additionally, those studies that did not differentiate between T1DM and T2DM were only 
included if the estimated T2DM sample ZDVRIWKHWRWDOVDPSOHSince the review was 
aimed at identifying three key aspects of diabetic nephropathy, we grouped selected studies 
XQGHU³SUHYDOHQFH´³SURJUHVVLRQ´DQG³RXWFRPHVVWXGLHV´ 
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Prevalence is defined as the number of cases existing at a given time in a given population 
usually expressed as a percentage (14). Since the definition of ³'LDEHWLFQHSKURSDWK\´
HQFRPSDVVHVWKRVHZLWK³LQFLSLHQWQHSKURSDWK\´GHILQHGDVWKHSUHVHQFHRI
PLFURDOEXPLQXULDDQGWKRVHZLWK³RYHUWQHSKURSDWK\´GHILQHGDVWKRVHZLWK
macroalbuminuria or overt proteinuria (15), we included all studies that measured either one 
or both of these outcomes in terms of prevalence of disease. Microalbuminuria and 
proteinuria were measured using different definitions across the majority of studies. In this 
review, microalbuminuria was defined as an albumin creatinine ratio (ACR) of >2 mg/mmol 
and proteinuria as >30 mg/mmol. Prevalence studies carried out in a representative 
population and examining at least 50 participants or more were included in the review. 
Progression studies included all studies that examined the progression/remission of 
albuminuria or estimated glomerular filtration rate (eGFR) decline. Studies where 
progression was based on CKD stages (1-5) as defined by the National Kidney Foundation 
Disease Outcome Quality Initiative working group guidelines on the classification of chronic 
kidney disease were included. Studies reporting the doubling of serum creatinine, or 
changes in creatinine clearance over time were also included in this review.  
Outcome studies included any studies related to the development of End-Stage Renal 
Disease (ESRD), when the kidneys permanently fail to work as a result of diabetic 
nephropathy in patients with T2DM.  The review was registered on PROSPERO 
CRD42018107350. 
 
Methods of the review 
The titles and abstracts of all articles identified by the broad literature search were assessed 
independently by two reviewers (CJ and SS). Studies that did not meet inclusion criteria 
were discarded. Full texts of selected articles were retrieved and assessed to determine if 
they met the inclusion criteria. A consensus was reached in case of any inconsistency with 
involvement of a third (KK).  Those studies which met the inclusion criteria were included in 
the review and data was extracted independently using a standard data extraction form.   
Quality scoring of selected studies 
We created a quality scoring system ranging from 0 to 6 points based on parameters 
identified by the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group 
(16). We used four pre-defined domains namely: selection criteria, measurement of 
exposure, objective diagnostic procedure and controlling for confounders to assess the 
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quality of the studies. Six points on the MOOSE reflects the highest study quality.  
(APPENDIX 1) 
Statistical analysis 
Pooled relative risks of microalbuminuria by ethnicity were estimated by fitting three random 
effects meta-analyses models. Heterogeneity between studies was assessed using the I-
squared statistics (17). For incidence of ESRD by ethnicity, data from studies was combined 
in a random effects meta-analysis model. Incidence was reported using incidence rate ratios 
(IRRs). In some studies the standard error of the IRR was calculated using published 
formula (18) (19) (20). Studies reporting hazard ratios, which can be assumed to estimations 
of the IRR, were also included in this review. As the impact of both age and duration of 
diabetes on the incidence of microalbuminuria may differ by ethnicity, we conducted meta-
regression analyses to adjust for both these factors. This was done by extracting data on 
mean age and duration by ethnicity and calculating the difference in means between ethnic 
groups for each study. By fitting this difference in means in a meta-regression model, the 
reported intercept will be the estimated rate ratio for ethnicity when the difference in mean 
age or duration is zero.  
For all meta-DQDO\VHVPRGHOVILWWHGIXQQHOSORWVDQG(JJHU¶VWHVWVZHUHFDUULHGRXWWR
assess for publication bias. Since there was substantial heterogeneity due to large 
differences in clinical or methodological nature between the studies in terms of the reporting 
of the progression of diabetes nephropathy, we decided a priori not to pool the data on 
nephropathy progression from the studies in a meta-analysis. Instead, we did a narrative 
synthesis of the nephropathy progression in the studies. STATA release 15 (Stata Corp, 
College Station, Texas, USA) was used for all statistical analyses. 
 
 
Results 
The search yielded a total of 2329 articles. 54 articles were retrieved for more detailed 
evaluation of the full text (Figure 1.1). APPENDIX 1 shows a flow diagram of the search 
strategy. Applying our inclusion criteria, 22 studies were excluded. 32 studies were identified 
as being suitable for this review, with the studies collectively reviewing 153,827 patients. The 
studies identified 84,718 White European participants, 24, 298 South Asian and 19,961 
African Caribbean participants. 
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Among the 32 studies, 18 were conducted in the UK, 3 in Netherlands, 3 in Australia, 7 in 
the USA and 1 study in Brazil. 
 
Study Quality 
Quality scores for 32 studies included in this review are shown in Table 1.2. Overall, the 
quality of studies was high (median 5, IQR 4-6), with thirteen studies achieving the highest 
score.  
Prevalence of diabetes nephropathy 
Data were extracted from 20 studies on prevalence of microalbuminuria in patients with 
T2DM by ethnic group (Table 1.1). The study by McGill et al. (21) was excluded from the 
meta-analysis as data was presented as odds of having microalbuminuria rather than the 
number/percentage of participants affected. The pooled prevalence rate ratio of 
microalbuminuria in South Asian compared to white European patients with type 2 diabetes 
was 1.14 (95% CI: 0.99, 1.32 p=0.07) (Fig 2.1). Similarly, for African Caribbeans vs White 
Europeans the pooled prevalence rate ratio was 1.06 (95% CI: 0.93, 1.20), p=0.35, and for 
African Caribbeans vs South Asians the pooled prevalence rate ratio was 1.08 (95% CI: 
0.93, 1.24), p=0.33 (Fig 2.2). The I-squared value from the three random effects meta-
analysis, indicated the amount of variation in the effect sizes attributable to study 
heterogeneity was moderate to high at 98.70%, 53.00% and 50.10% respectively. After 
adjusting for differences in mean age and duration of diabetes between ethnic groups in a 
meta-regression analyses, there was still no statistically significant differences in in the 
prevalence of microalbuminuria (Table 3 in supplementary material).  The estimated 
prevalence rate ratios in South Asian vs White European was 1.15 (0.99, 1.32) p=0.570, 
African Caribbeans vs White European was 0.97 (95% CI: 0.63, 1.46) p=0.826, and South 
Asian vs African Caribbean was 0.95 (0.85, 1.06), p=0.524.  
  
Progression of diabetes nephropathy 
Five studies reported the progression of diabetic nephropathy (Table 2). Three studies 
measured progression of disease in South Asians, White Europeans and Afro Caribbeans 
(22) (23) (24) whereas two only compared progression in South Asians and White 
Europeans (25) (26). Three out of the five studies recorded annual eGFR decline (22) (23). 
The remaining two studies assessed progression of renal disease by recording serial serum 
creatinine measurements (26), assessing time taken for serum creatinine to double (24) and 
lastly measuring creatinine clearance over a set period of time (25). In summary, in three of 
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the studies, differences were noted in the progression of renal deterioration among the three 
ethnic groups, thus confirming the alternative hypothesis. Two studies showed no 
differences in the progression of renal deterioration. Assessing the annual decline in eGFR, 
one study found a non-significant decline in Afro-&DULEEHDQ¶VRI-2.12 ml/min/1.73m2 
FRPSDUHGWR:KLWH(XURSHDQ¶V-1.93 ml/min/1.73m2) and South Asians (-1.85 
ml/min/1.73m2) (22). The second study reported a significant difference in all three groups 
with White Europeans demonstrating an annual decline of -0.64 (95% CI -0.68, -0.60), South 
Asians of -0.77 (-0.81, -0.74) and Afro-Caribbeans of -0.55 (95% CI -0.61, -0.48) (23).  
Similarly, Chandie-Shaw et al (25) assessed eGFR decline but over a 5-year period. They 
found a decline of 32 ml/min in South Asians and 22 ml/min in White Europeans (p=0.049). 
Of the remaining two studies, one study found a mean estimated rise in creatinine (ß) of 5.36 
(95% CI, 2.21-8.52) vs 2.22 (95% CI, 1.31-3.14) in White Europeans and 3.14 (95% CI, 
0.82-5.46) in Afro-&DULEEHDQ¶VS (24). Finally, Koppiker et al, (26) compared the 
interaction between creatinine-ethnicity using serum creatinine as a time dependent variable. 
Results from extended Cox modelling found a risk ratio (95% CI) of 1.00 (0.99, 1.02) 
between South Asians and White Europeans.  A meta-analysis was not performed since 
measurement of disease progression differed across the studies.  
 
End-Stage Renal Disease  
Ten studies reported the incidence of ESRD in the three ethnicities relevant to this review. 
However, three of the studies where data were extracted were not included in the study; 
Chandie Shaw et al (27) and Gerchman et al (28)  reported odds of having eGFR rather than 
incidence rates, and Omer Ali (22) reported different clinical outcomes relating to decline in 
kidney function.
The estimated pooled IRR for ESRD was significantly higher in African Caribbeans vs White 
Europeans 2.75 (95% CI: 2.01, 3.48 p<0.001) (Fig 3.1). The pooled IRR for South Asians vs 
Western Europeans (Fig 3.2) was 0.88 (95% CI: -0.18, 1.94), p=0.104, from three studies. 
Between study heterogeneity was again high, with I-squared values of 86.9% and 76.6% for 
the two meta-analyses.  
$OO(JJHU¶VWHVWVIRUSXEOLFDWLRQELDVZHUHQRQ-significant, and an examination of the funnel 
plots raised no concerns for the presence of publication bias. The number of studies 
included in the meta-analyses models were fairly small, and heterogeneity was high.
 
 
9 
 
Discussion  
This systematic review and meta-analysis of published prevalence studies showed no 
significant differences in the prevalence of microalbuminuria in South Asians and Afro-
Caribbeans compared to White Europeans with T2DM.  Of the 5 studies identified for this 
review for various markers of renal impairment progression, when comparing the rates of 
deterioration between south Asians and white Caucasians, the results were inconsistent with 
preponderance towards a high rate of disease progression in south Asians compared to 
white Caucasians. This is consistent with previous literature (23) (27) (24). Similarly, an 
inconsistent pattern of renal disease progression rates was found in studies that compared 
blacks with white Caucasians, but two (22) (24) out of the three studies identified showed a 
higher rate in blacks compared to white Caucasians. These results are in keeping with 
studies assessing the progression of renal disease in non-diabetics. In the observational 
analysis of combined data from the Third National Health and Nutrition Examination Survey 
and the US Renal Data System, which includes patients without diabetes, even though the 
prevalence of CKD was similar among African Americans and among persons of white 
race/ethnicity, the estimated progression rates among those with CKD were 5-fold higher 
among African Americans (29). It is acknowledged that some of the differences found in this 
systematic review for prevalence of microalbuminuria between ethnic groups, may be due to 
differences in age and duration of diabetes by ethnicity. This was explored through meta-
regression analyses, although the analyses that could be carried out were limited as not all 
studies reported the relevant data. Meta-regression analyses lack power, as only study level 
data is available. To really understand the complexity of these relationships individual patient 
data is needed.  
 
 
With regards to ESRF, there was a significant difference in the IRR between African 
Caribbeans vs White Europeans. In the African American Study of Kidney Disease and 
Hypertension (AASK) (30) (31) (32), which did not meet the inclusion criteria of this review, a 
beneficial effect of RAAS inhibition was noted which is likely to be along the proteinuria axis, 
as this has been confirmed in other landmark trials (33) (34). Despite these benefits, other 
studies have shown that African Americans who are treated with RAAS therapy continue to 
progress during the long term follow ups (35). This progression to ESRF could be occurring 
across other non-albuminuric pathways that yet remain to be established (36). Other 
reasons including genetic predisposition (particularly with recent discovery of apolipoprotein 
L1) (37), obesity, low socioeconomic status, high-risk health behaviours (such as poor diet), 
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and limited access to healthcare could also account for the continuous progression.  In our 
analysis, despite the finding of equivalence in prevalence of albuminuria between the African 
Caribbeans and White Europeans, the IRR of ESRF was 2.75, suggesting an alternative 
pathway to ESRF in addition to the albuminuric pathway, probably more predominant in the 
African Caribbean race.  
Whatever the reasons for this disparity, standardized interventions and improved health care 
delivery in these high-risk individuals is required to reduce the variations in renal outcomes 
in these populations. In a recent post-hoc analysis of the Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) trial looking at the longitudinal change in eGFR, time to 
development of microalbuminuria, macroalbuminuria, incident CKD, and kidney failure or 
serum creatinine > 3.3 mg/dL (38), it was noted that even though the mean values of systolic 
blood pressure, hemoglobin A1c microalbuminura, macroalbuminira and serum creatinine 
levels were higher in blacks at baseline, both blacks and whites achieved similar rapid 
improvement of both clinical parameters, which were maintained during study follow-up. This 
suggests that optimization of the delivery of diabetes care prior to the development of CKD 
may lead to similar short-term kidney outcomes, irrespective of race. 
 
Strengths and Limitations of the review 
The strengths of this systematic review are the use of a broad search strategy performed on 
multiple databases and the involvement of two independent reviewers for the study selection 
and the data extraction phases. Limitations in the studies include estimating the prevalence 
of microalbuminuria and proteinuria using albumin creatinine ratio (ACR) that was reported 
on the basis of a single random urine sample or an early morning sample. The use of a 
single ACR value may underestimate microalbuminuria in those with a higher muscle mass, 
including males and could be affected by variations in diet or physical exercise (39). The 
presence of selection bias is another limiting factor which can have a considerable impact on 
prevalence estimates of the different stages of diabetic nephropathy. Different methods for 
ascertainment of outcomes were also used in the studies, making this a limiting factor during 
comparisons.  
The number of studies in this review was limited because seven of the 22 excluded studies 
was due to lack of differentiation between the types of diabetes as a cause of underlying 
diabetic nephropathy. This is an important differentiating feature which has been ignored in 
these studies. Generally, it is estimated that 20-30% of people with T1DM develop 
proteinuria, and a large number progress to renal failure (40). Fewer patients with T2DM 
progress to ESRD but despite this they account for a large majority of patients on renal units. 
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This is largely due to the higher prevalence of T2DM compared to T1DM. Racial differences 
have also been observed between T1DM and T2DM patients with nephropathy (12).  
 
Conclusion   
This systematic review and meta-analysis of published prevalence studies showed that the 
pooled estimates of microalbuminuria, were numerically higher in South Asians compared to 
White Europeans, however these results were not statistically significant. This review was 
able to identify few studies relating to progression of diabetic nephropathy between South 
Asians and White Europeans. Our results were inconsistent with South Asians and African 
Caribbeans demonstrating a faster progression than White Europeans in some of the 
studies, however due to considerable heterogeneity between these studies, no definite 
conclusion can be drawn on whether disease progression is significantly different in these 
individuals. This review found a significantly higher IRR of ESRF in African Caribbeans 
compared to White Europeans. These results have highlighted the need for more research 
on the potential non-albuminuric pathways of progression to ESRF with a focus on ethnic 
origin to explore if a correlation between the two exists. This systematic review has also 
revealed the sparsity in studies looking at the progression of diabetic nephropathy in patients 
with T2DM. This has highlighted the need for more research studies to determine if ethnic 
disparities do exist in disease progression and outcomes of T2DM nephropathy which can 
guide early, targeted interventions and improved health care delivery in these high-risk 
individuals.  
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